Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma

Biomedical Chromatography

Volumn 28, Issue 10, 2014, Pages 1366-1370

  Luethi, Dino ^a   Durmus, Selvi ^b   Schinkel, Alfred H ^b   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b,c   Sparidans, Rolf W ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Bioanalytical assay; LC MS MS; Multikinase inhibitor; Regorafenib

Indexed keywords

DISEASES; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; MASS SPECTROMETERS; MASS SPECTROMETRY; METHANOL;

BIOANALYTICAL; BIOANALYTICAL ASSAYS; CONCENTRATION RANGES; LC-MS-MS; LC.MS/MS; MULTIKINASE INHIBITOR; PROTEIN PRECIPITATION; REGORAFENIB; SAMPLE PRETREATMENT; TANDEM MASS SPECTROMETRIC;

LIQUID CHROMATOGRAPHY;

ACETONITRILE; FORMIC ACID; METHANOL; REGORAFENIB; SORAFENIB; WATER; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG STABILITY; DRUG STORAGE; ELECTROSPRAY; ELUTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; CHEMISTRY; HUMAN; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; LINEAR MODELS; MICE; PHENYLUREA COMPOUNDS; PYRIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84908360110     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3176     Document Type: Article

References (17)

1. Bayer Inc. Stivarga product monograph, 2013. Available from: http://www.bayer.ca/files/STIVARGA-PM-ENG-2OCT2013-159750.pdf (accessed 14 January 2014).
2. Bruix J, Tak W-Y, Gasbarrini A, Santoro A, Colombo M, Lim H-Y, Mazzaferro V, Wiest R, Reig M, Wagner A and Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. European Journal of Cancer 2013; 49: 3412-3419.
3. Center for Drug Evaluation and Research of the US Department of Health and Human Services, Food and Drug Administration. Bioanalytical method validation, 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 6 July 2013).
4. Center for Drug Evaluation and Research of the US Department of Health and Human Services, Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000ClinPharmR.pdf, 2012 (accessed 14 January 2014).
5. Committee for Medicinal Products for Human Use, European Medicines Agency. Guidline on validation of bioanalytical methods. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500018062.pdf, 2009 (accessed 6 July 2013).
6. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T and Quinn DI. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncology 2012; 13: 1055-1062.
7. European Medicines Agency, 2013. EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002573/WC500149167.pdf (accessed 14 January 2014).
8. Food and Drug Administration. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 2012; 26: 896.
9. Food and Drug Administration. FDA approves regorafenib (Stivarga) for GIST. Oncology (Williston Park) 2013; 27: 164.
10. Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH and Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2013; 934: 22-25.
11. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O and Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012; 18: 2658-2667.
12. Sennino B and McDonald DM. Controlling escape from angiogenesis inhibitors. Nature Reviews Cancer 2012; 12: 699-709.
13. Sparidans RW, Vlaming MLH, Lagas JS, Schinkel AH, Schellens JHM and Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metaboliet. Journal of Chromatography B: Analytical Technologies in the Biomedical Life Sciences 2009; 877: 269-276.
14. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M, Christensen O, Jeffers M, Heinig R, Boix O and Mross K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. British Journal of Cancer 2012; 106: 1722-1727.
15. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, Mitsunaga S, Hashizume K, Ito Y and Sasaki Y. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Investigational New Drugs 2014; 32: 104-112.
16. van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ and Hartigh J. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2013; 937: 33-43.
17. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH and Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer 2011; 129: 245-255.